CHI3L1 and myeloid sarcoma: Mechanistically, Chi3l1 can exert cytotoxic effects by inducing neurite length retraction and reducing neuronal survival only in neurons but not in other central nervous system cells, indicating that Chi3l1 is a potential therapeutic target for MS patients [197].